drug development to treat diseases that cause BLINDNESS
Targeting the Root Causes of Disease
drug development to treat diseases that cause BLINDNESS
Targeting the Root Causes of Disease
ABOUT ERMARIS BIO, PBC
Our Vision
Our Expertise
Our Expertise
Our mission is to improve the healthspan of individuals by developing novel, efficacious, and accessible treatments for serious diseases.
Our Expertise
Our Expertise
Our Expertise
With over 20 years of experience each in drug discovery and development, our team has the knowledge and expertise to efficiently progress drug candidates through clinical development.
Our Focus
Our Expertise
Our Focus
We are developing a pipeline of best-in-class small molecules to treat diseases that cause blindness.
Targeting retinal diseases with progressive vision loss
Geographic Atrophy (GA)
GA is an advanced form of age-related macular degeneration (AMD), characterized by atrophic lesions that can result from bisretinoid accumulation. Risk Factors are increasing age and family history. About 1 million people in the US are affected. The first two drugs were approved by the FDA in 2023, both requiring administration by intravitreal injection (IVT).
Stargardt Disease (STGD1)
STGD1 is an autosomal recessive disease caused by mutations in the ABCA4 gene. This leads to accumulation of toxic retinal deposits of bisretinoids. STGD1 is classified as a rare disease, that affects about 30,000 people in the US. Onset is often early, by adolescence, and there is no currently approved treatment.
erm-001 is an oral bi-specific small molecule
Biologic Targets
ERM-001 was designed to bind to two serum proteins: retinol binding protein 4 (RBP4, shown in yellow and red) and transthyretin (TTR, shown in purple and blue). RBP4 inhibition drives efficacy, while TTR stabilization improves the safety profile and provides benefits to patients who also have cardiomyopathy or peripheral neuropathy caused by TTR amyloidosis.
Efficacy
ERM-001 dosed orally once per day, decreased RBP4 levels dose-dependently in preclinical models to a therapeutic threshold needed to treat GA and STGD1. This resulted in near complete blockade of retinal bisretinoid accumulation.
Drug Properties
ERM-001 has durable best-in-class pharmacokinetics with optimal target coverage at once per day oral dosing.
ermaris bio preclinical pipeline
ERM-001 is a pre-clinical small molecule development candidate.
ERM-101 is a patent-pending improvement to ERM-001.
ERM-201 has utility to treat more diseases.